Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m2 on days 1, 4, 8, 11, 22, 25...

Descripció completa

Dades bibliogràfiques

Autors principals:	María-Victoria Mateos, Albert Oriol, Laura Rosiñol, Felipe de Arriba, Noemí Puig, Jesús Martín, Joaquín Martínez-López, María Asunción Echeveste, Josep Sarrá, Enrique Ocio, Gemma Ramírez, Rafael Martínez, Luis Palomera, Angel Payer, Rebeca Iglesias, Javier de la Rubia, Adrian Alegre, Ana Isabel Chinea, Joan Bladé, Juan José Lahuerta, Jesús-F. San Miguel
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2015-08-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/7467
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!